
Guardian Doubles Washington Presence with Addition of Nine HUD Communities
'This expansion reflects our continued commitment to providing housing for all and strengthens our ability to serve more Washington housing communities with the care and attention they deserve.' Tom Brenneke, President, Guardian
Share
The transition includes a total of 1,300 apartment homes located in nine counties, spanning from Vancouver to Port Townsend and Spokane to Chehalis, marking a significant expansion of Guardian's affordable housing management portfolio. These communities provide affordable housing options for seniors and families throughout Washington.
The phased transition took effect on February 1, 2025, for four communities, and April 1, 2025, for the remaining five. With this addition, Guardian doubled its presence in Washington, and the Evergreen State now makes up 20% of its managed portfolio.
'We're honored to be a trusted partner in preserving housing that helps these communities thrive,' said Tom Brenneke, President of Guardian. 'This expansion reflects our continued commitment to providing housing for all and strengthens our ability to serve more Washington housing communities with the care and attention they deserve.'
Guardian brings more than 20 years of experience in the management of affordable housing, including Low-Income Housing Tax Credit (LIHTC) and HUD-subsidized properties. As property manager, Guardian will oversee all operational aspects of the nine communities, including compliance, maintenance, marketing, and resident support, with a focus on supporting long-term housing preservation.
About Guardian
Guardian is a developer, owner, and operator of multifamily properties, providing innovative real estate solutions dedicated to community and housing for all. Based in the Pacific Northwest, our customer-focused team is committed to supporting and lifting the communities we serve. Since 2002, Guardian has developed or acquired 11,000 multifamily units and 350,000 square feet of commercial space. With more than 450 team members, our management portfolio consists of 135 communities across four states. For more information, visit gres.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
8 hours ago
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from J.P. Morgan
J.P. Morgan analyst David Low maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per yesterday and set a price target of A$48.00. The company's shares closed yesterday at A$42.88. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Low is a 4-star analyst with an average return of 7.6% and a 57.02% success rate. Low covers the Healthcare sector, focusing on stocks such as Resmed, Cochlear , and CSL. Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per is a Strong Buy with an average price target of A$45.42, a 5.92% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a A$48.00 price target. The company has a one-year high of A$44.12 and a one-year low of A$32.04. Currently, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an average volume of 835K.


Business Insider
8 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Resmed (RMD) and Envista Holdings (NVST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch + Lomb Corporation (BLCO – Research Report), Resmed (RMD – Research Report) and Envista Holdings (NVST – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch + Lomb Corporation (BLCO) J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Bausch + Lomb Corporation on July 30 and set a price target of $13.00. The company's shares closed last Friday at $13.50, close to its 52-week low of $13.16. According to Marcus is a 4-star analyst with an average return of 8.8% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Merit Medical Systems. Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $14.69, implying an 8.2% upside from current levels. In a report issued on July 30, Needham also maintained a Hold rating on the stock. Resmed (RMD) J.P. Morgan analyst David Low maintained a Buy rating on Resmed yesterday and set a price target of $310.00. The company's shares closed last Friday at $279.20. According to Low is a 4-star analyst with an average return of 7.6% and a 57.0% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Cochlear, and CSL. Resmed has an analyst consensus of Strong Buy, with a price target consensus of $295.40, implying a 4.8% upside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $298.00 price target. Envista Holdings (NVST) J.P. Morgan analyst Rachel Vatnsdal maintained a Hold rating on Envista Holdings yesterday and set a price target of $20.00. The company's shares closed last Friday at $20.83. According to Vatnsdal is a 1-star analyst with an average return of -1.2% and a 39.3% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Twist Bioscience, and Myriad Genetics. Envista Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $22.17, which is a 9.6% upside from current levels. In a report issued on July 29, UBS also maintained a Hold rating on the stock with a $22.00 price target.
Yahoo
8 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio